NeoGenomics, Inc. (NEO) Stake Lowered by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank decreased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 13.4% during the first quarter, Holdings Channel reports. The institutional investor owned 5,039 shares of the medical research company’s stock after selling 779 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in NeoGenomics were worth $103,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in shares of NeoGenomics by 26.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 882,244 shares of the medical research company’s stock valued at $13,543,000 after buying an additional 182,172 shares during the period. AQR Capital Management LLC increased its stake in shares of NeoGenomics by 117.8% in the 3rd quarter. AQR Capital Management LLC now owns 27,641 shares of the medical research company’s stock valued at $424,000 after buying an additional 14,949 shares during the period. Teachers Advisors LLC increased its stake in shares of NeoGenomics by 8.9% in the 3rd quarter. Teachers Advisors LLC now owns 122,219 shares of the medical research company’s stock valued at $1,876,000 after buying an additional 9,997 shares during the period. Morgan Stanley increased its stake in shares of NeoGenomics by 716.1% in the 3rd quarter. Morgan Stanley now owns 1,056,917 shares of the medical research company’s stock valued at $16,225,000 after buying an additional 927,403 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of NeoGenomics by 24.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,839,641 shares of the medical research company’s stock valued at $58,939,000 after buying an additional 743,245 shares during the period. Hedge funds and other institutional investors own 82.84% of the company’s stock.
Shares of NeoGenomics stock traded up $0.13 during trading on Friday, reaching $21.25. 977,209 shares of the company were exchanged, compared to its average volume of 1,181,154. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.35. NeoGenomics, Inc. has a twelve month low of $11.05 and a twelve month high of $23.85. The stock has a market cap of $2.03 billion, a PE ratio of 163.46 and a beta of 0.91.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. NeoGenomics had a positive return on equity of 3.07% and a negative net margin of 0.14%. The business had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $89.71 million. During the same period in the previous year, the firm earned $0.04 earnings per share. The firm’s quarterly revenue was up 50.8% compared to the same quarter last year. Analysts expect that NeoGenomics, Inc. will post 0.19 EPS for the current fiscal year.
NEO has been the subject of several research reports. CIBC raised NeoGenomics from a “neutral” rating to an “outperform” rating and lowered their target price for the company from $18.00 to $15.00 in a research note on Tuesday, March 12th. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 20th. Zacks Investment Research cut NeoGenomics from a “buy” rating to a “hold” rating in a research note on Saturday, March 2nd. Finally, Needham & Company LLC lifted their price objective on NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, March 29th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. NeoGenomics presently has a consensus rating of “Buy” and a consensus price target of $20.00.
In other NeoGenomics news, Director Raymond R. Hipp sold 18,889 shares of NeoGenomics stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $18.90, for a total transaction of $357,002.10. Following the transaction, the director now directly owns 297,580 shares in the company, valued at $5,624,262. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider William Bonello sold 7,200 shares of NeoGenomics stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $23.53, for a total value of $169,416.00. Following the transaction, the insider now owns 13,935 shares in the company, valued at $327,890.55. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 602,400 shares of company stock worth $12,693,858. Corporate insiders own 12.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://transcriptdaily.com/2019/05/25/neogenomics-inc-neo-stake-lowered-by-zurcher-kantonalbank-zurich-cantonalbank.html.
NeoGenomics Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: What is a growth and income fund?
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source